NCT00139035

Effects of Cyclosporine A on Pancreatic Insulin Secretion

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 16 (planned)
• Sponsor: University of Oslo School of Pharmacy · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Our primary aim is to investigate if cyclosporine A reduces insulin secretion.

Detailed description

Our primary aim is to investigate if cyclosporine A may reduce insulin secretion by 20% or more. In order to get cyclosporine A naïve patients we will perform this investigation in dialysis patients on the waiting list for a renal transplantation. In addition we will investigate if also the peripheral insulin sensitivity and endothelia function is affected by cyclosporine A treatment in these patients. Since these patients will be treated with cyclosporine A we will also measure cyclosporine pharmacokinetics at the time of investigation and repeat this investigation at the time of the first week following transplantation in order to evaluate if a pretransplant cyclosporine dose can be of value in predefining the dose to be used at the time of transplantation.

Conditions

• Chronic Renal Failure

Interventions

Type	Name	Description
DRUG	cyclosporine A

Timeline

• Start date: 2005-04-01
• Primary completion: 2006-01-01
• First posted: 2005-08-30
• Last updated: 2012-11-02

Locations

1 site across 1 country: Norway